Sacubitril/valsartan: um guia prático revisitado
To the Editor, Since the publication in the May 2019 issue of our paper ''Sacubitril/valsartan: a practical guide'', 1 which was based on the PARADIGM-HF 2 trial results, new evidence has become available with recent data from the TRANSITION and PIONEER-HF trials. 3, 4 On the basis of this new evidence, as the authors of the original practical guide we would like to add new considerations to our previous recommendations on the use of this drug.
Although it represents a worsening of prognosis in heart failure with reduced ejection fraction (HFrEF), hospitalization for acute heart failure constitutes an opportunity to initiate and successfully up-titrate guideline-recommended therapies. The international guidelines support the initiation and up-titration of all disease-modifying therapy (DMT) early after hemodynamic stabilization following an acute heart failure event in order to improve prognosis, particularly during the vulnerable phase early after discharge. 5 Although this has been demonstrated for previous classes of heart failure DMT, there was still a gap in evidence on the optimal time for the initiation of sacubitril/valsartan in HFrEF patients after an acute decompensation.
The TRANSITION and PIONEER-HF trials evaluated the initiation of sacubitril/valsartan in severe HFrEF patients after stabilization following an acute heart failure episode, both before and early after discharge, with no run-in phase, closer to the challenges of everyday clinical practice.
The TRANSITION study assessed the safety and tolerability of sacubitril/valsartan in patients admitted with HFrEF, after stabilization following an acute heart failure episode. Patients were enrolled to initiate sacubitril/valsartan either in the hospital or shortly after discharge. 6 At 10 weeks, when more than 86% of patients had been receiving sacubitril/valsartan for two weeks or longer without interruption, about half the patients in the study had achieved the primary endpoint, which was a target dose of 200 mg of sacubitril/valsartan twice daily within 10 weeks in both groups. 5 The incidence of adverse events and discontinuation of sacubitril/valsartan due to adverse events was also similar in both in-hospital and outpatient settings. 3 The tolerability of sacubitril/valsartan in TRANSITION appears to be comparable to that reported for beta-blockers and ACEIs/ARBs under real-life conditions. 3, 7 PIONEER-HF was designed to assess the safety, tolerability and efficacy of in-hospital initiation of sacubitril/valsartan compared to enalapril in stabilized HFrEF patients who had been admitted for acute decompensation. 8 The primary endpoint was the time-averaged proportional change in NT-proBNP from baseline through weeks 4 and 8. 4, 8 Patients treated with sacubitril/valsartan achieved a 47% reduction from baseline in time-averaged NT-proBNP, compared to a 25% reduction with enalapril, translating into a statistically significant 29% greater reduction with sacubitril/valsartan over the ACEI (95% CI: 0.63-0.81; p<0.0001). 4 Significant reductions in NT-proBNP were observed in sacubitril/valsartan patients as early as one week after treatment initiation. 4 There were no new safety signals identified, and the safety profile was comparable to that observed in PARADIGM-HF. 2, 4 Rates of serious adverse events occurring with a frequency of ≥0.5% were similar between the sacubitril/valsartan and enalapril groups. 4 In a pre-specified exploratory analysis, the composite endpoint of death, rehospitalization for HF, left ventricular assist device implantation or listing for cardiac transplant occurred in 41 (9.3%) patients in the sacubitril/valsartan group and in 74 (16.8%) in the enalapril group (HR 0.54, 95% CI 0.37-0.79; p=0.001). 4 The benefit was driven by reductions in death and rehospitalization among patients treated with sacubitril/valsartan. The number needed to treat to prevent one such clinical event during eight weeks of followup was 13. 4 Moreover, TRANSITION and PIONEER-HF are the first randomized studies to provide data on the use of sacubitril/valsartan in new-onset and ACEI/ARB-naive HFrEF patients. In fact, approximately 34% of patients in PIO-NEER and 29% in TRANSITION were newly diagnosed, with no prior history of heart failure, and slightly more than 50% of patients in PIONEER and 24% in TRANSITION were not receiving ACEI/ARB therapy at the time of admission. 3, 4 Recently presented data from PIONEER-HF also showed that sacubitril/valsartan, titrated to target dose based on systolic blood pressure during hospitalization, had the same beneficial effect on the primary and safety endpoints in ACEI/ARB-naive patients. 9 In summary, the TRANSITION and PIONEER-HF results provide complementary data to PARADIGM-HF, addressing https://doi.org/10.1016/j.repc.2019.05.007 0870-2551/© 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved. 
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IN WHOM AND WHEN?
Indications:
• Adult patients with heart failure and reduced ejection fraction (LVEF <40%)
• Replacement of ACEI/ARB in outpatients who remain in NYHA class II-IV despite treatment with an ACEI/ARB, a beta-blocker and an MRA • Before discharge, in stabilized patients admitted with a primary diagnosis of decompensated or de novo acute heart failure, irrespective of prior ACEI/ARB exposure • Patients should have SBP ≥100 mmHg and serum potassium level <5.5 mmol/l. previous gaps in evidence. They support the use of sacubitril/valsartan both during hospital stay and in outpatient settings. Although there are still a few unanswered questions and unpublished results from both trials, the data from PIONEER-HF and TRANSITION support the in-hospital initiation of sacubitril/valsartan in all NYHA II-III patients early after stabilization, and independently of prior HF diagnosis or ACEI/ARB exposure. There are now grounds for initiating therapy in HFrEF with ACEI safely as a first option, in both in-hospital and outpatient settings.
On the basis of this new information, our paper ''Sacubitril/valsartan: a practical guide'' should be revisited as in Table 1 .
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